Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ultragenyx Pharmaceutical

37.82
-1.0700-2.75%
Pre-market: 37.80-0.0200-0.05%05:04 EDT
Volume:323.20K
Turnover:12.28M
Market Cap:3.50B
PE:-6.02
High:38.76
Open:38.64
Low:37.70
Close:38.89
Loading ...

Company Profile

Company Name:
Ultragenyx Pharmaceutical
Exchange:
NASDAQ
Establishment Date:
2010
Employees:
1294
Office Location:
60 Leveroni Court,Novato,California,United States
Zip Code:
94949
Fax:
- -
Introduction:
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Directors

Name
Position
Daniel G. Welch
Chairman and Director
Emil D. Kakkis
Director,President and Chief Executive Officer
Clay B. Siegall
Director
Deborah Dunsire
Director
Lars G. Ekman
Director
Matthew K. Fust
Director
Michael Narachi
Director
William Aliski
Director

Shareholders

Name
Position
Emil D. Kakkis
Director,President and Chief Executive Officer
Shalini Sharp
Chief Financial Officer and Executive Vice President
Camille L. Bedrosian
Chief Medical Officer and Executive Vice President
Dennis Huang
Chief Technical Operations Officer and Executive Vice President
Jayson Dallas
Chief Commercial Officer and Executive Vice President
John R. Pinion II
Chief Quality Officer and Executive Vice President of Translational Sciences
Karah Parschauer
General Counsel and Executive Vice President
Thomas Kassberg
Chief Business Officer and Executive Vice President